Nadide
CAS 53-84-9
Nadide (CAS 53-84-9) is a Phase 2 pharmaceutical compound with 1 bioactivity target and 39 adverse event associations.
Compound Identity
Matched identifiers and naming fields for the pharmaceutical compound record.
Clinical Development Phase
Highest clinical development phase rendered from the matched compound identifier rows.
Cross-Reference to Cosmetics
Same-CAS ingredient record found in the cosmetics vertical.
Bioactivity & Target Interactions
Target-level activity records with assay counts, activity type, and measured value where present.
| Target | Activity | Value | Assays | Organism |
|---|---|---|---|---|
| - | IC50 | 19976.309999999998 nM | 1 | - |
IUPHAR Ligand-Target Data
Curated ligand-target interaction rows with action, affinity, and literature identifiers.
| Target | Action | Affinity | PubMed |
|---|---|---|---|
| P2Y 11 receptor P2RY11 |
Full agonist | - | 16926152 |
| TRPM2 TRPM2 |
Agonist | - | 16601673|11509734|11804595|12564954 |
Drug Names / RxNorm
Normalized drug-name vocabulary rows, RxCUIs, and source abbreviations.
| Name | RxCUI | Type | Source |
|---|---|---|---|
| NADIDE | 1044975 | SU | MTHSPL |
Frequently Asked Questions
Short answers generated only from the same visible source-linked rows on this page.
What is Nadide used for in pharmaceutical contexts?
Nadide (CAS 53-84-9) is rendered as a pharmaceutical compound from the matched source rows; no DailyMed product-name rows are present in this page query.
What are the known adverse events for Nadide?
Nadide has 39 DrugCentral/FAERS adverse event associations. Rendered reaction terms include Anxiety, Bone pain, Fatigue, Lethargy, Pneumonia. Signal rows are source-linked records and should not be read as incidence rates or causality conclusions.
Is Nadide also used in cosmetics?
Yes. The ingredients table has a same-CAS cosmetic profile for NAD+ Cosmetic with EU status "permitted".
What clinical phase is Nadide in?
Nadide is rendered with ChEMBL max phase 2.